No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
231 |
4. Check minimum number of eventsNone |
231 |
5. Include endpointsNone |
231 |
6. Filter based on genotype QC (FinnGen only) |
231 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E83
- Name in latin
- Perturbationes metabolismi magnesii
Similar endpoints
↥List of similar endpoints to
Disorders of magnesium metabolism
based on the number of shared cases.
Similar with more cases:
- Disorders of mineral metabolism
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1471 | 688 | 778 |
| Only index persons | 1406 | 660 | 746 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 64.94 | 65.77 | 64.25 |
| Only index persons | 65.12 | 66.02 | 64.32 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 231 | 102 | 129 |
| Unadjusted period prevalence (%) | 0.05 | 0.03 | 0.06 |
| Median age at first event (years) | 66.91 | 63.58 | 69.54 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 200
- Matched controls
- 1998
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E83.4
ICD-10 Finland
Disorders of magnesium metabolism
+∞
289.5
200
*
E87.6
ICD-10 Finland
Hypokalaemia
244.2
67.7
66
*
E83.51
ICD-10 Finland
Hypocalcemia
457.3
66.7
63
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
9.5
37.2
88
152
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
126.2
30.7
32
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
25.4
29.3
41
20
130
Kela drug reimbursment
Malignant tumour
9.4
29.0
65
97
WW500
NOMESCO Finland
Blood transfusion
20.7
26.2
39
23
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.6
25.9
61
97
N02AA05
ATC
oxycodone; systemic
6.8
25.0
72
153
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.0
24.6
113
412
E86
ICD-10 Finland
Volume depletion
+∞
24.5
23
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
13.1
24.4
44
42
C03CA01
ATC
furosemide; systemic
5.3
24.3
93
280
A03FA01
ATC
metoclopramide; systemic, rectal
5.4
23.6
87
249
D64.9
ICD-10 Finland
Anaemia, unspecified
8.0
22.9
56
93
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
10.5
22.8
46
55
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.0
21.6
85
256
H02AB02
ATC
dexamethasone; systemic
6.1
20.0
61
135
R56.8
ICD-10 Finland
Other and unspecified convulsions
12.3
19.6
36
35
TPH04
NOMESCO Finland
Cathetrisation of vein
4.8
19.5
79
241
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
19.4
127
604
AA1AD
NOMESCO Finland
CT of head and brain
4.5
19.2
83
270
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.2
19.1
95
352
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.5
18.8
63
155
N17.9
ICD-10 Finland
Acute renal failure, unspecified
21.1
17.9
26
14
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
8.5
17.7
40
57
TPH07
NOMESCO Finland
Cathetrisation of artery
6.0
17.5
52
110
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
21.8
17.4
25
13
JN4BD
NOMESCO Finland
Extensive body CT
5.3
17.0
57
139
E83.39
ICD-10 Finland
Other disorder of phosphorus metabolism
+∞
16.9
16
*
A04AA02
ATC
granisetron; systemic, transdermal
7.7
16.3
39
61
WX302
NOMESCO Finland
Thoracal epidural anesthesy
8.4
16.0
36
51
JN4AD
NOMESCO Finland
Body CT examination
6.4
15.9
44
84
SPAT1262
SPAT
Handing over of treatment supplies
4.3
15.8
69
219
R11
ICD-10 Finland
Nausea and vomiting
7.3
15.0
37
60
B01AB10
ATC
tinzaparin; parenteral
6.2
14.9
42
82
E61.2
ICD-10 Finland
Magnesium deficiency
+∞
14.8
14
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
11.4
14.5
27
27
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
8.1
14.0
32
46
JN3AD
NOMESCO Finland
Abdominal CT examination
5.7
13.9
42
89
J01MA12
ATC
levofloxacin; systemic
4.0
13.9
64
211
Z51.5
ICD-10 Finland
Palliative care
7.0
13.8
35
59
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
12.2
13.4
24
22
GD1AD
NOMESCO Finland
Thorax CT examination
9.1
13.4
28
35
UJF32
NOMESCO Finland
Coloscopy
3.4
13.2
82
342
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
8.7
12.6
27
35
F10.31
ICD-10 Finland
Withdrawal symptoms caused by alcohol with seizures
138.3
12.6
13
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
5.5
12.5
38
81
A11CC03
ATC
alfacalcidol; systemic
17.3
12.4
19
12
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.5
12.3
47
129
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.5
12.0
65
241
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.0
12.0
94
452
XX3DW
NOMESCO Finland
Time consuming IT work
4.3
11.9
48
138
ZX095
NOMESCO Finland
Combined chemoradiotherapy
32.2
11.8
15
5
F10.25
ICD-10 Finland
Alcohol dependence continuous use
18.4
11.4
17
10
A02BC02
ATC
pantoprazole; systemic
3.0
11.2
151
1013
I10
ICD-10 Finland
Essential (primary) hypertension
2.8
11.1
135
844
JDB10
NOMESCO Finland
Percutaneous gastrostomy
23.0
10.9
15
7
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
63.5
10.7
12
*
M04AA01
ATC
allopurinol; systemic
4.1
10.7
44
128
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
7.9
10.7
24
34
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
13.1
10.6
18
15
E83.50
ICD-10 Finland
Hypercalcemia
+∞
10.5
10
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.3
10.4
32
69
WX408
NOMESCO Finland
General anesthesy, balanced
2.9
10.3
78
360
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.2
10.3
65
265
D70.82
ICD-10 Finland
Drug-induced neutropenia
15.7
10.2
16
11
F10.29
ICD-10 Finland
Addiction caused by alcohol UNS
11.5
10.0
18
17
N02BE01
ATC
paracetamol; systemic, rectal
4.1
10.0
183
1446
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
7.5
10.0
23
34
N02AX02
ATC
tramadol; systemic, rectal
2.6
9.9
107
609
B03BA03
ATC
hydroxocobalamin; parenteral
6.2
9.8
26
47
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.8
9.7
24
39
ZX070
NOMESCO Finland
Intensity modified radiotherapy
10.9
9.7
18
18
205
Kela drug reimbursment
Chronic hypertension
2.9
9.7
73
333
F10.39
ICD-10 Finland
Withdrawal symptoms caused by alcohol UNS
18.7
9.5
14
8
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
23.0
9.5
13
6
F10.26
ICD-10 Finland
Alcohol dependence periodic alcoholism
23.0
9.5
13
6
C08CA01
ATC
amlodipine; oral
2.7
9.4
85
429
C07AB07
ATC
bisoprolol; oral
2.6
9.4
111
653
WZC30
NOMESCO Finland
Teaching
3.4
9.4
50
179
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
19.7
9.1
13
7
JFB00
NOMESCO Finland
Partial resection of small intestine
13.4
9.0
15
12
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
25.4
9.0
12
5
WVC10
NOMESCO Finland
Subcutaneous infusion of drugs
25.4
9.0
12
5
A41.9
ICD-10 Finland
Sepsis, unspecified
7.8
9.0
20
28
WX402
NOMESCO Finland
General anaesthesia
3.4
9.0
48
172
I50.9
ICD-10 Finland
Heart failure, unspecified
4.2
8.9
34
92
103
Kela drug reimbursment
Diabetes, insulin-treated
2.8
8.9
69
319
B01AB05
ATC
enoxaparin; parenteral
2.7
8.8
76
371
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
52.3
8.8
10
*
F10.20
ICD-10 Finland
Alcohol dependence currently independent
12.4
8.7
15
13
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.6
8.7
41
134
F10.00
ICD-10 Finland
Alcohol-related acute intoxication uncomplicated
17.3
8.7
13
8
H02AB06
ATC
prednisolone; systemic
2.5
8.7
110
663
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
7.3
8.6
20
30
F10.30
ICD-10 Finland
Withdrawal symptoms caused by alcohol uncomplicated
21.1
8.6
12
6
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
3.8
8.5
37
113
EBA15
NOMESCO Finland
Extraction of large number of teeth
7.7
8.5
19
27
E87.5
ICD-10 Finland
Hyperkalaemia
93.8
8.5
9
*
R79.0
ICD-10 Finland
Abnormal level of blood mineral
+∞
8.4
8
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
15.3
8.3
13
9
T36
ICD-10 Finland
Poisoning by systemic antibiotics
8.7
8.3
17
21
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.7
8.2
65
300
C03DA01
ATC
spironolactone; oral
4.3
8.2
30
78
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
10.7
8.2
15
15
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
23.1
8.1
11
5
A04AA01
ATC
ondansetron; systemic, rectal
4.2
8.0
30
80
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
5.2
8.0
24
51
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
11.5
7.9
14
13
UJC01
NOMESCO Finland
Scopy of lower throat
15.8
7.8
12
8
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
46.8
7.8
9
*
G72.8
ICD-10 Finland
Other specified myopathies
19.3
7.7
11
6
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
10.7
7.7
14
14
A46
ICD-10 Finland
Erysipelas
3.4
7.7
38
129
L01BC06
ATC
capecitabine; oral
6.1
7.6
20
36
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
8.2
7.6
16
21
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.7
7.5
33
102
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.4
7.4
36
120
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
5.2
7.4
22
46
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.4
7.4
78
420
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
5.5
7.4
21
42
K70.1
ICD-10 Finland
Alcoholic hepatitis
+∞
7.3
7
*
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.5
7.3
25
61
WX002
NOMESCO Finland
Sedation and analgesia
2.9
7.3
50
209
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.7
7.3
55
245
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
20.9
7.2
10
5
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.9
7.2
29
83
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.9
7.2
29
83
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
12.7
7.2
12
10
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
9.3
7.2
14
16
A04AA55
ATC
palonosetron, combinations; systemic
9.3
7.2
14
16
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
7.5
7.2
16
23
EP1AE
NOMESCO Finland
Neck ultrasound examination
4.8
7.1
23
53
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
6.3
7.1
18
31
SPAT1148
SPAT
Treatment of chronic ulcer or burn
3.2
7.0
38
136
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.5
6.9
32
103
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
4.6
6.9
23
55
SPAT1255
SPAT
Intravenous administration of medicine
4.2
6.9
25
65
D70.89
ICD-10 Finland
Neutropenic splenomegaly
41.5
6.8
8
*
WX892
NOMESCO Finland
Monitored bed care
4.1
6.8
26
71
A04AD12
ATC
aprepitant; systemic
8.3
6.7
14
18
N19
ICD-10 Finland
Unspecified kidney failure
9.2
6.7
13
15
SPAT1229
SPAT
Assessment of need for aid
4.1
6.6
25
68
J01MA02
ATC
ciprofloxacin; systemic
2.2
6.6
86
507
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
3.6
6.5
29
91
P16
ICPC
Acute alcohol abuse
14.9
6.5
10
7
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
3.7
6.5
27
80
M10.9
ICD-10 Finland
Gout, unspecified
4.1
6.5
24
64
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.2
6.5
92
559
A02BC05
ATC
esomeprazole; systemic
2.2
6.4
95
590
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.8
6.4
41
166
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
11.6
6.4
11
10
WX872
NOMESCO Finland
Intensive care
5.4
6.4
18
36
D07AA02
ATC
hydrocortisone; topical
3.0
6.3
37
141
8140/3-C20.9
ICD-O-3
Adenocarcinoma, NOS, of rectum, NOS
7.4
6.3
14
20
F10.40
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol without seizures
18.7
6.3
9
5
K70.4
ICD-10 Finland
Alcoholic hepatic failure
+∞
6.3
6
*
N08.39
ICD-10 Finland
Glomerular disorders in diabetes mellitus microalbuminuria
+∞
6.3
6
*
JFF10
NOMESCO Finland
Loop enterostomy
+∞
6.3
6
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
27.6
6.3
8
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.9
6.2
24
67
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
3.4
6.2
29
95
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.7
6.1
26
78
P15
ICPC
Chronic alcohol abuse
9.0
6.1
12
14
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.4
6.1
21
52
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
10.5
6.1
11
11
T81.3
ICD-10 Finland
Disruption of operation wound, not elsewhere classified
10.5
6.1
11
11
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.2
6.1
31
108
B81
ICPC
Anaemia vit B12/folate deficiency
5.4
6.0
17
34
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
115
253
8.06
56.14
3.8
2.3
2.2
2.3
g/l
1.63
110
236
120
281
7.81
54.95
3.8
2.2
10.2
14.1
umol/l
6.68
113
267
111
240
7.98
54.94
3.6
2.3
20.7
24.8
%
1.62
97
208
75
106
10.00
53.95
4.8
3.7
101.1
95.0
ng/l
0.13
67
90
79
122
9.32
52.78
3.1
1.5
—
—
—
0
0
88
157
8.44
51.78
3.1
2.0
389.4
354.0
nmol/l
0.62
82
143
142
437
6.84
47.68
3.7
1.9
3.0
3.2
mg/l
0.34
130
388
93
193
7.39
47.04
3.1
2.5
0.2
0.2
g/l
2.00
86
179
207
924
12.94
46.26
24.4
6.2
1.2
1.2
mmol/l
7.88
152
790
96
213
7.00
45.24
3.4
4.6
248.5
249.4
u/l
0.02
90
201
42
35
14.44
43.13
2.7
2.4
14.0
15.7
%
0.73
17
15
195
855
9.22
43.08
18.4
5.3
1.2
1.2
mmol/l
9.22
188
783
167
646
6.72
41.98
6.7
3.5
2.3
2.4
mmol/l
6.84
149
570
107
290
6.01
40.11
2.4
1.9
—
—
—
0
0
51
76
8.33
34.24
1.5
2.6
1.4
1.5
g/l
0.04
46
64
40
44
10.79
34.03
2.1
1.2
—
—
—
0
0
165
724
5.48
33.02
4.2
2.1
67.3
78.6
nmol/l
4.77
155
641
83
209
5.64
33.01
8.0
3.0
—
—
—
0
0
70
151
6.22
32.97
10.4
3.5
3.2
2.2
mmol/l
0.70
63
117
56
106
6.65
29.96
5.7
3.3
1.6
2.1
mmol/l
0.38
44
89
35
41
9.88
28.28
1.7
1.4
205.2
222.6
ug/g
0.16
23
23
198
1097
6.63
27.47
20.5
9.6
4.8
3.9
e9/l
3.79
191
977
76
206
5.01
27.20
2.2
1.9
—
—
—
0
0
118
460
4.20
25.96
2.4
1.5
20.7
20.9
nmol/l
0.03
102
386
64
157
5.26
25.67
2.6
2.2
64.2
66.9
g/l
1.23
55
146
74
208
4.76
25.13
2.3
1.9
—
—
—
0
0
96
336
4.18
24.28
2.4
1.7
1494.0
1295.6
nmol/l
0.84
71
263
153
744
4.13
23.91
4.9
2.4
387.8
138.3
ug/l
2.46
145
683
36
54
7.71
23.70
2.3
1.4
—
—
—
0
0
27
31
9.73
21.98
1.4
1.6
—
—
—
0
0
33
49
7.69
21.86
1.6
2.0
—
—
—
0
0
33
49
7.69
21.86
2.9
2.4
1.9
1.4
mg/l
1.20
33
44
148
737
3.81
21.57
5.3
3.0
—
—
—
0
0
29
38
8.58
21.31
1.5
1.8
—
—
—
0
0
19
13
15.84
21.30
1.3
1.5
—
—
—
0
0
97
375
3.74
20.72
8.2
3.1
2.4
2.5
mmol/l
0.22
87
335
66
197
4.29
20.35
2.5
1.7
2.1
1.5
%
2.97
46
168
32
50
7.27
20.22
1.6
1.9
—
—
—
0
0
129
607
3.55
20.14
5.5
3.1
38.6
32.9
u/l
1.08
124
573
140
721
3.39
18.36
7.1
3.2
35.5
32.7
ng/l
0.13
129
523
16
11
15.55
17.79
1.4
1.6
—
—
—
0
0
16
11
15.55
17.79
1.4
1.6
—
—
—
0
0
21
24
9.53
17.04
1.3
1.7
—
—
—
0
0
34
69
5.61
16.52
2.6
3.5
—
—
—
0
0
113
540
3.14
16.32
4.1
3.0
2687.9
1088.3
ng/l
3.45
104
461
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
29
51
6.36
16.31
4.4
2.8
0.3
0.3
u/ml
0.01
20
26
16
13
13.15
16.19
1.4
1.7
—
—
—
0
0
139
750
3.14
16.15
3.2
1.9
84.7
97.0
pmol/l
2.18
99
390
64
218
3.68
16.05
11.4
6.9
1.6
1.3
mmol/l
0.23
57
174
21
27
8.46
15.54
1.4
1.8
—
—
—
0
0
116
575
3.04
15.51
3.9
2.9
0.9
0.4
e6/l
0.80
94
434
153
885
3.16
15.48
6.9
4.0
—
—
—
0
0
88
375
3.18
15.32
2.0
1.7
501.9
444.8
pmol/l
0.64
73
312
14
10
14.84
15.17
1.5
1.5
—
—
—
0
0
14
10
14.84
15.17
1.5
1.5
—
—
—
0
0
41
108
4.40
14.61
1.9
1.3
—
—
—
0
0
57
191
3.63
14.54
12.4
7.3
106.1
120.3
g/l
6.76
57
183
22
33
7.26
14.29
1.4
1.7
—
—
—
0
0
25
45
6.11
13.68
8.9
8.4
2641.1
138.3
iu/ml
—
7
8
59
211
3.41
13.54
7.8
5.2
48.6
58.6
ug/l
0.08
54
177
113
584
2.83
13.53
5.1
3.7
14.5
5.1
mg/mmol
1.55
78
343
27
53
5.64
13.52
1.2
1.9
—
—
—
0
0
17
20
9.10
13.42
1.9
2.5
33.1
33.5
pg
0.09
17
20
43
127
3.93
13.09
10.5
7.5
92.8
94.0
%
0.65
43
127
21
33
6.90
13.06
1.4
1.6
—
—
—
0
0
28
61
5.09
12.49
1.3
3.0
52.5
143.9
mg/l
0.41
22
48
28
61
5.09
12.49
1.3
3.0
45.5
34.4
mg/l
0.74
21
50
22
39
6.13
12.20
1.5
1.7
—
—
—
0
0
81
368
2.85
12.15
1.5
1.2
1.2
1.4
u/ml
0.07
19
91
91
440
2.76
12.12
4.7
2.4
—
—
—
0
0
29
67
4.81
12.08
2.0
1.7
—
—
—
0
0
21
36
6.32
12.02
3.3
2.9
1.5
1.1
%
0.27
16
30
58
220
3.18
11.98
3.2
2.9
10.8
8.7
umol/l
0.21
52
195
21
38
5.98
11.39
3.8
3.0
67.3
56.4
%
2.04
21
38
37
111
3.78
10.95
1.8
1.6
—
—
—
0
0
20
36
5.99
10.90
3.1
2.4
5.4
4.2
e9/l
0.72
20
36
28
71
4.35
10.38
2.4
1.9
—
—
—
0
0
79
380
2.64
10.37
1.7
1.7
1.7
1.4
mg/l
0.45
65
304
13
15
9.12
10.33
1.4
1.3
8309.8
52221.0
e6/l
—
5
7
176
1253
2.70
9.64
6.5
3.0
103.4
48.1
u/l
4.16
171
1173
58
249
2.77
9.43
23.1
22.1
1.3
1.3
inr
—
8
35
42
151
3.18
9.36
2.1
2.6
7.3
9.8
ug/l
0.51
33
137
36
125
3.23
8.47
12.2
6.8
25.4
25.1
mmol/l
0.13
36
115
15
26
6.10
8.44
1.6
2.2
—
—
—
0
0
93
526
2.29
8.24
5.4
3.6
0.0
0.0
estimate
0.00
49
176
10
11
9.46
8.14
1.3
1.2
—
—
—
0
0
25
70
3.88
8.10
1.2
1.3
3.4
3.3
g/l
0.25
17
55
90
505
2.28
8.10
5.0
2.6
5027.7
7269.0
umol/l
0.17
78
431
184
1393
2.58
7.94
5.4
3.5
15.8
14.9
pmol/l
3.47
166
1253
21
53
4.26
7.80
2.1
1.3
—
—
—
0
0
14
25
5.90
7.64
1.6
2.2
—
—
—
0
0
10
12
8.67
7.63
2.9
2.3
—
—
—
0
0
16
33
5.13
7.53
2.0
1.4
—
—
—
0
0
25
74
3.67
7.49
1.2
1.2
8.0
7.4
g/l
0.39
18
58
25
74
3.67
7.49
1.2
1.2
—
—
—
0
0
22
60
3.95
7.38
1.9
1.5
—
—
—
0
0
28
91
3.36
7.29
6.6
2.0
1.8
1.3
%
0.65
28
91
16
34
4.98
7.28
2.1
1.4
—
—
—
0
0
16
34
4.98
7.28
2.1
1.4
—
—
—
0
0
137
936
2.14
7.28
5.4
3.3
0.0
0.0
estimate
0.00
56
184
11
16
7.17
7.21
2.5
2.4
6.0
6.2
mmol/l
0.08
11
16
23
66
3.76
7.20
1.2
1.2
11.2
10.1
g/l
0.38
17
58
137
939
2.13
7.18
7.1
4.4
0.0
0.0
estimate
0.00
56
178
18
44
4.35
6.95
2.4
1.5
—
—
—
0
0
13
24
5.68
6.85
1.6
1.2
—
—
—
0
0
24
74
3.50
6.77
1.2
1.2
4.1
3.7
g/l
0.74
17
55
19
50
4.05
6.68
1.4
1.3
—
—
—
0
0
26
87
3.24
6.46
13.3
2.9
57.9
48.0
%
1.29
26
87
10
15
6.92
6.36
1.2
1.0
—
—
—
0
0
21
62
3.63
6.31
1.2
1.3
0.1
1.0
g/l
1.22
16
57
135
953
2.00
6.16
5.7
3.3
0.0
0.0
estimate
0.50
55
178
12
23
5.45
6.07
2.4
1.5
16.6
17.3
ug/l
0.05
12
23
9
6
15.53
5.95
5.1
3.2
—
—
—
0
0
14
32
4.59
5.85
1.1
1.1
—
—
—
0
0
15
37
4.27
5.72
1.2
1.2
—
—
—
0
0
15
37
4.27
5.72
1.2
1.2
—
—
—
0
0
221
1933
4.31
5.67
54.3
13.5
29.6
24.6
mg/l
1.60
209
1494
14
34
4.32
5.44
2.2
1.4
—
—
—
0
0
14
34
4.32
5.44
2.2
1.4
—
—
—
0
0
14
35
4.19
5.25
2.2
1.4
—
—
—
0
0
62
350
2.05
5.17
7.2
3.7
103.2
447.9
ng/l
1.45
53
271
37
169
2.42
5.15
4.6
2.8
29.0
31.1
u/l
0.16
31
144
107
731
1.86
5.07
6.0
3.4
—
—
—
0
0
180
1458
2.06
4.99
6.7
4.0
22.7
12.3
mm/h
7.61
164
1332
13
32
4.25
4.96
1.2
1.2
—
—
—
0
0
57
319
2.04
4.84
4.5
2.9
4.8
1.4
e6/l
1.16
33
184
9
10
9.31
4.83
1.4
1.5
—
—
—
0
0
9
10
9.31
4.83
1.4
1.5
—
—
—
0
0
7
5
14.37
4.60
1.0
1.2
—
—
—
0
0
7
5
14.37
4.60
1.4
1.8
—
—
—
0
0
10
22
4.71
4.34
1.1
1.5
—
—
—
0
0
9
13
7.15
4.20
1.1
1.2
—
—
—
0
0
9
13
7.15
4.20
1.1
1.2
—
—
—
0
0
9
13
7.15
4.20
1.4
2.2
—
—
—
0
0
15
47
3.34
4.13
1.5
1.7
—
—
—
0
0
10
23
4.50
4.13
1.1
1.0
—
—
—
0
0
10
23
4.50
4.13
3.9
2.0
6.6
3.1
nmol/l
—
10
23
21
84
2.65
3.84
1.1
2.0
39.1
39.4
u/l
0.02
16
76
7
9
7.98
3.58
1.7
2.6
115.9
91.9
%
—
7
9
57
352
1.82
3.54
3.2
2.7
2.1
0.7
e6/l
0.97
32
217
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
6
6
10.22
3.51
1.5
1.2
144.7
232.7
%
—
6
6
6
6
10.22
3.51
1.0
1.2
—
—
—
0
0
6
6
10.22
3.51
1.0
1.0
—
—
—
0
0
9
18
5.16
3.40
2.0
1.9
—
—
—
0
0
9
18
5.16
3.40
2.0
1.9
—
—
—
0
0
9
18
5.16
3.40
2.0
1.9
—
—
—
0
0
7
10
7.18
3.39
3.9
2.9
87.3
61.5
nmol/l
—
7
10
14
50
2.92
3.14
1.6
1.3
—
—
—
0
0
199
1760
1.94
3.09
6.7
4.2
2.1
1.9
mu/l
0.66
184
1591
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
8
7.66
3.07
1.0
1.3
—
—
—
0
0
6
10
6.12
2.71
1.7
2.4
—
—
—
0
0
8
20
4.10
2.59
1.0
1.3
—
—
—
0
0
5
7
7.27
2.56
1.4
1.1
—
—
—
0
0
6
11
5.57
2.56
1.7
1.1
—
—
—
0
0
130
1059
1.52
2.51
3.1
2.7
—
—
—
0
0
13
51
2.64
2.49
3.6
2.7
641.4
120.2
ug/min
—
5
32
12
46
2.70
2.40
1.2
1.5
—
—
—
0
0
7
17
4.21
2.38
1.1
1.0
—
—
—
0
0
10
35
2.94
2.33
2.9
1.4
486.2
281.5
mu/l
—
10
30
8
23
3.56
2.29
1.1
1.0
—
—
—
0
0
6
13
4.71
2.28
1.0
1.2
—
—
—
0
0
6
13
4.71
2.28
6.3
2.8
—
—
—
0
0
7
21
3.40
1.98
1.7
1.2
—
—
—
0
0
5
11
4.62
1.95
1.4
2.5
2200.4
783.3
u/ml
—
5
11
7
22
3.25
1.89
2.0
2.4
—
—
—
0
0
220
2085
2.16
1.75
63.8
16.1
93.7
79.1
umol/l
3.03
220
2085
25
155
1.69
1.54
4.5
2.6
47.8
66.6
ml/min/173m2
1.79
17
58
11
51
2.21
1.53
1.7
1.2
—
—
—
0
0
11
51
2.21
1.53
1.7
1.2
—
—
—
0
0
5
16
3.17
1.44
1.4
1.6
—
—
—
0
0
6
24
2.54
1.31
1.0
1.3
—
—
—
0
0
6
24
2.54
1.31
2.2
4.1
—
—
—
0
0
200
1873
1.51
1.31
52.2
12.7
73.5
79.8
ml/min/173m2
3.14
194
1558
175
1604
1.38
1.26
62.3
16.6
14.9
13.7
%
13.87
175
1575
6
26
2.34
1.19
1.0
1.4
—
—
—
0
0
188
1987
0.71
1.16
5.3
4.9
2.4
2.8
mmol/l
5.29
167
1815
35
253
1.45
1.15
23.5
6.5
—
—
—
0
0
8
41
1.98
1.10
1.1
1.2
—
20.3
—
0
5
185
1729
1.35
1.03
41.8
14.2
35.6
40.0
%
4.99
90
1219
7
36
1.97
0.98
1.1
1.1
195.1
345.0
u/ml
—
7
24
7
37
1.92
0.95
1.1
1.2
—
—
—
0
0
100
893
1.21
0.72
4.4
5.2
1.8
2.7
ug/l
1.18
78
807
186
1942
0.78
0.71
5.0
4.3
1.4
1.5
mmol/l
0.92
164
1780
7
41
1.73
0.70
1.4
1.4
182.6
323.2
pmol/l
—
7
41
187
1950
0.78
0.70
5.0
4.4
4.3
4.6
mmol/l
3.60
166
1796
7
45
1.57
0.49
1.0
1.4
—
—
—
0
0
13
93
1.42
0.49
1.6
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
12
88
1.38
0.41
5.8
3.6
21.7
120.3
u/ml
1.02
12
76
27
322
0.82
0.40
1.2
1.3
26.5
35.5
iu/ml
—
6
104
18
225
0.78
0.40
1.1
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
6
44
1.37
0.34
1.2
1.3
—
2.0
—
0
6
183
1882
0.87
0.34
4.8
3.9
1.5
1.2
mmol/l
4.40
159
1726
48
535
0.87
0.34
1.9
1.7
1.4
1.3
mmol/l
0.36
42
435
7
97
0.71
0.31
1.1
1.0
—
—
—
0
0
8
63
1.28
0.28
1.6
2.3
—
—
—
0
0
27
309
0.86
0.27
1.2
1.3
1.3
14.7
u/ml
—
9
109
5
40
1.26
0.22
1.2
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
189
1853
1.11
0.21
8.7
5.3
41.2
39.3
mmol/mol
1.56
173
1713
6
49
1.23
0.20
5.0
1.7
—
—
—
0
0
6
49
1.23
0.20
1.0
1.2
—
—
—
0
0
6
50
1.21
0.20
1.2
1.3
—
2.2
—
0
12
25
263
0.94
0.05
1.5
1.4
—
—
—
0
0
71
726
0.97
0.05
3.4
4.6
20.5
21.1
%
0.12
27
380
13
123
1.06
0.01
2.7
1.7
—
—
—
0
0
54
542
1.00
0.00
2.6
3.2
0.7
0.7
ug/l
0.12
33
394
14
136
1.03
0.00
2.9
1.9
—
—
—
0
0
193
1928
1.01
0.00
6.1
4.5
6.3
5.9
mmol/l
2.60
176
1764
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
6
61
0.98
0.00
6.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_MG_MET and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_MG_MET | 6.28 [3.89, 10.13] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.391 |
During the follow-up period (1.1.1998 — 31.12.2019), 185 out of 478 females with E4_MG_MET died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_MG_MET | 8.216 [5.17, 13.05] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 237 out of 529 males with E4_MG_MET died.
Mortality risk
Mortality risk for people of age
years, who have E4_MG_MET.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.659% | 1.418% |
| 5 | 3.779% | 8.106% |
| 10 | 8.898% | 19.789% |
| 15 | 16.579% | 34.075% |
| 20 | 28.077% | 50.984% |
Relationships between endpoints
↥Index endpoint: E4_MG_MET – Disorders of magnesium metabolism
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data